The Woman Who Wasn't There

Total Page:16

File Type:pdf, Size:1020Kb

The Woman Who Wasn't There Cases That Test Your Skills The woman who wasn’t there Ahmed Janjua, MD, Daniel Rapport, MD, and Gina Ferrara, MD How would you Since a night of heavy drinking 4 years ago, Ms. A has felt handle this case? detached from reality and confused. Various antidepressants Visit CurrentPsychiatry.com to input your answers and anxiolytics have not helped. What would you try next? and see how your colleagues responded CASE Feeling detached borhood, having her car broken into, her father’s Ms. A, age 23, presents to our clinic complain- disapproval of her fiancé, and wanting to get ing of feeling detached for the past 4 years. married. She drank heavily in college, but has She says she feels “fuzzy all the time, like I lost used alcohol infrequently since then. touch with reality 4 years ago and really miss Ms. A’s father has a history of anxiety. She it.” She complains of “confused thinking,” ex- describes him as domineering and her mother cessive tiredness and weakness, depression, as very emotional and always wanting to be and anxiety. She says, “It feels like I’m watch- her friend. Ms. A says she struggles with re- ing my life on television; I don’t feel any emo- lationships, employment, and plans for ad- tions.” These symptoms began immediately vancement, all of which are moderately to after a college party, which the police stopped severely affected by her depersonalization because of underage drinking. She says, “I symptoms. During the initial appointment, don’t know why, but that party set it off, and it we diagnose Ms. A with generalized anxiety feels like I am in a dream all the time.” disorder, panic disorder, and major depressive For the last 4 years, Ms. A has been work- disorder (MDD). ing as a waitress and is now engaged. She presents to our clinic because the treatments Which diagnoses would you include among she has been receiving are ineffective and she the differential diagnosis? wants to feel her emotions again, especially a) posttraumatic stress disorder (PTSD) before her wedding. b) MDD with psychotic features Ms. A has no history of mania, depression, c) depersonalization disorder or psychosis. She says she was an anxious d) schizophrenia, undifferentiated type child and suffered from anorexia nervosa be- e) psychosis not otherwise specified tween age 13 and 14. She experienced occa- sional panic attacks beginning in high school The authors’ observations that were triggered by feeling overwhelmed Depersonalization symptoms can occur in or frustrated with not feeling normal. During a variety of situations, including: these panic attacks, Ms. A experienced tight- Dr. Janjua is a third-year psychiatry resident, University of ness in her chest and dizziness. She denies sui- Toledo Medical Center, Toledo, OH. Dr. Rapport is associate cidal or homicidal ideation or attempts. professor of psychiatry and director of the consultation-liaison At age 18, she was sexually assaulted. Ongo- service, University of Toledo Medical Center, Toledo, OH. Current Psychiatry Dr. Ferrara is second-year child/adolescent psychiatry fellow at 62 April 2010 ing stressors include living in a dangerous neigh- the University of Southern California, Los Angeles, CA. Cases That Test Your Skills Table 1 Assessing for depersonalization: 3 rating scales Scale Description Cambridge 29-item, self-report questionnaire meant to capture frequency and Depersonalization Scale5 duration of depersonalization symptoms over the previous 6 months Depersonalization Covers a range of axis I and II psychopathology Severity Scale6 Dissociative Experiences 28-item, self-report instrument to measure dissociation Scale7 • mentally healthy persons suffering from assault, she does not meet criteria for PTSD acute stressors, fatigue, or drug use because she denies re-experiencing the as- • neuropsychiatric conditions such as sault, hyperarousal, and avoidance behaviors. Clinical Point epilepsy Ms. A meets all 4 DSM-IV-TR criteria for Rating scales and • migraine depersonalization disorder (Table 2, page 64). • anxiety disorders She experiences persistent feelings of de- DSM-IV-TR criteria • depressive disorders tachment, which cause her considerable dis- can help differentiate • schizophrenia.1 tress. Her reality testing is intact and these transient symptoms Transient depersonalization symptoms experiences are not due to a general medical from a disorder and are common and have been found in 2.4% condition, another mental disorder, or direct assess severity of the general population.2 Community physiological effects of a substance. surveys using standardized diagnostic in- terviews reveal 1-month prevalence rates of Which medications would you consider for 1.6% to 1.9% in 2 UK samples.3,4 Deperson- Ms. A? alization symptoms are brief and less de- a) benzodiazepine plus a tricyclic anti- bilitating than depersonalization disorder. depressant (TCA) Depersonalization rarely presents as a b) selective serotonin reuptake inhibitor primary disorder, when symptoms persist (SSRI) plus a benzodiazepine chronically. Rating scales (Table 1)5-7 and c) trazodone plus bupropion DSM-IV-TR criteria (Table 2, page 64) can d) atypical antipsychotic plus a benzodiaz- help assess symptom severity and differen- epine and a TCA tiate transient symptoms from a disorder. Psychiatric conditions that commonly are comorbid with depersonalization disorder TREATMENT Insufficient response appear in Table 3 (page 71).8 Triggers for a Ms. A’s previous psychiatrist prescribed various first episode of depersonalization disorder SSRIs and selective serotonin-norepinephrine include: reuptake inhibitors, including sertraline, esci- • psychological stressors (31%) talopram, citalopram, paroxetine, and venla- • substance abuse (25%) faxine, for depression and anxiety with little or • physical stressor (12%) no benefit. When she presented at our clinic, • situational stressor (17%) Ms. A was taking clonazepam, 0.25 mg as • social and/or relationship problems needed, and fluvoxamine, 50 mg/d, which she (10%) said helped her anxiety a little, but not deper- • trauma (6%) sonalization symptoms. She received support- • panic/anxiety (2%).8 ive psychotherapy provided during biweekly Although Ms. A experiences deperson- 30-minute medication management visits. alization—constant numbness and empti- We add aripiprazole, 2.5 mg/d, to augment Current Psychiatry ness—when she thinks about the sexual fluvoxamine’s antidepressant effect and reduce Vol. 9, No. 4 63 Cases That Test Your Skills Table 2 DSM-IV-TR criteria for depersonalization disorder A. Persistent and recurrent experiences of feeling detached from oneself and as if one is an outside observer of one’s mental processes or body. B. During the depersonalization experience, reality testing remains intact. C. The depersonalization causes clinically significant distress or impairment in social, occupational, or other important areas of functioning. D. The depersonalization experience does not occur exclusively during the course of another mental disorder, such as schizophrenia, panic disorder, acute stress disorder, or another dissociative disorder, and is not due to the direct physiological effects of a substance (eg, a drug of abuse or a medication) or a general medical condition (eg, temporal lobe epilepsy). Source: Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association; 2004 Clinical Point her anxiety and dissociative symptoms. At the anxiety and depression. After 2 weeks, Ms. A Depersonalization next visit 5 weeks later, she reports her dep- says her anxiety and depression have resolved disorder is associated ersonalization symptoms gradually lessened completely but the depersonalization symp- with HPA axis from 10 to 6 on a 10-point self-report scale. toms persist. We restart amantadine, 100 mg dysregulation We discontinue fluvoxamine after 5 weeks as needed, for anorgasmia. and lower basal because it no longer significantly contributes Because of her persistent complaints of de- to her recovery. We add amantadine, 100 mg/d, personalization, after discussion with Ms. A, cortisol levels based on the belief that dopamine augmenta- we decide to return to what had helped her tion might help reduce her symptoms. Ms. A at the beginning of treatment and restart ar- reports improved depersonalization symptoms ipiprazole, 2.5 mg/d. Four months later, she over the next 4 weeks (5/10). However, a week reports her depersonalization symptoms have later she says she feels her anxiety is worsen- resolved completely. At this time, her regimen ing the depersonalization symptoms. We start consists of clomipramine, 50 mg at bedtime, buspirone, 7.5 mg/d titrated to 15 mg/d over diazepam, 10 mg at bedtime, and aripiprazole, 4 weeks, Ms. A reports feeling worse so we dis- 2.5 mg/d. continue the drug. Next Ms. A complains of excessive sleepiness, Which neurotransmitter systems have been which seems to be related to amantadine, so we implicated in depersonalization disorder? discontinue it. We start bupropion, 150 mg/d a) HPA axis and titrate it to 450 mg/d, which we hope will b) serotonin system reduce her fatigue, anxiety, depersonalization, c) norepinephrine-dopamine system and depression. Bupropion’s effect on norepi- d) dopamine-serotonin system nephrine and dopamine reuptake and a study of e) all of the above autonomic blunting in depersonalization9 justify our selection. The authors’ observations After 3 months, Ms. A stops taking aripip- The neurobiology of emotion processing razole because it
Recommended publications
  • Paranoid – Suspicious; Argumentative; Paranoid; Continually on The
    Disorder Gathering 34, 36, 49 Answer Keys A N S W E R K E Y, Disorder Gathering 34 1. Avital Agoraphobia – 2. Ewelina Alcoholism – 3. Martyna Anorexia – 4. Clarissa Bipolar Personality Disorder –. 5. Lysette Bulimia – 6. Kev, Annabelle Co-Dependant Relationship – 7. Archer Cognitive Distortions / all-of-nothing thinking (Splitting) – 8. Josephine Cognitive Distortions / Mental Filter – 9. Mendel Cognitive Distortions / Disqualifying the Positive – 10. Melvira Cognitive Disorder / Labeling and Mislabeling – 11. Liat Cognitive Disorder / Personalization – 12. Noa Cognitive Disorder / Narcissistic Rage – 13. Regev Delusional Disorder – 14. Connor Dependant Relationship – 15. Moira Dissociative Amnesia / Psychogenic Amnesia – (*Jason Bourne character) 16. Eylam Dissociative Fugue / Psychogenic Fugue – 17. Amit Dissociative Identity Disorder / Multiple Personality Disorder – 18. Liam Echolalia – 19. Dax Factitous Disorder – 20. Lorna Neurotic Fear of the Future – 21. Ciaran Ganser Syndrome – 22. Jean-Pierre Korsakoff’s Syndrome – 23. Ivor Neurotic Paranoia – 24. Tucker Persecutory Delusions / Querulant Delusions – 25. Lewis Post-Traumatic Stress Disorder – 26. Abdul Proprioception – 27. Alisa Repressed Memories – 28. Kirk Schizophrenia – 29. Trevor Self-Victimization – 30. Jerome Shame-based Personality – 31. Aimee Stockholm Syndrome – 32. Delphine Taijin kyofusho (Japanese culture-specific syndrome) – 33. Lyndon Tourette’s Syndrome – 34. Adar Social phobias – A N S W E R K E Y, Disorder Gathering 36 Adjustment Disorder – BERKELEY Apotemnophilia
    [Show full text]
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20100227876A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0227876 A1 Rech (43) Pub. Date: Sep. 9, 2010 (54) METHODS OF REDUCING SIDE EFFECTS Publication Classi?cation OF ANALGESICS (51) Int CL A61K 31/485 (2006.01) A61K 31/40 (2006.01) (75) Inventor: Richard H. Rech, Okemos, MI A61K 31/445 (2006-01) (Us) A61K 31/439 (2006.01) (52) US. Cl. ........................ .. 514/282; 514/409; 514/329 (57) ABSTRACT Correspondence Address: The invention provides for compositions and methods of MARSHALL, GERSTEIN & BORUN LLP reducing pain in a subject by administering a combination of 233 SOUTH WACKER DRIVE, 6300 WILLIS mu-opioid receptor agonist, kappal-opioid receptor agonist TOWER and a nonselective opioid receptor antagonist in amounts CHICAGO, IL 60606-6357 (US) effective to reduce pain and ameliorate an adverse side effect of treatment combining opioid-receptor agonists. The inven tion also provides for methods of enhancing an analgesic effect of treatment With an opioid-receptor agonist in a sub (73) Assignee: RECHFENSEN LLP, RidgeWood, ject suffering from pain While reducing an adverse side effect NJ (US) of the treatment. The invention also provides for methods of reducing the hyperalgesic effect of treatment With an opioid receptor agonist in a subject suffering from pain While reduc ing an adverse side effect of the treatment. The invention (21) Appl. No.: 12/399,629 further provides for methods of promoting the additive anal gesia of pain treatment With an opioid-receptor agonist in a subject in need While reducing an adverse side effect of the (22) Filed: Mar.
    [Show full text]
  • Drug Class Review on Second Generation Antidepressants
    Drug Class Review on Second Generation Antidepressants FINAL REPORT November 2004 The Agency for Healthcare Research and Quality has not yet seen or approved this report Gerald Gartlehner, M.D., M.P.H. Richard A. Hansen, Ph.D. Leila Kahwati, M.D., M.P.H. Kathleen N. Lohr, Ph.D. Bradley Gaynes, M.D., M.P.H Tim Carey, M.D., M.P.H. Produced by RTI-UNC Evidence-based Practice Center Cecil G. Sheps Center for Health Services Research University of North Carolina at Chapel Hill 725 Airport Road, CB# 7590 Chapel Hill, NC 27599-7590 Tim Carey, M.D., M.P.H., Director Final Report Drug Effectiveness Review Project Table of Contents Introduction........................................................................................................................ 4 Overview................................................................................................................. 4 Scope and Key Questions ....................................................................................... 7 Methods............................................................................................................................. 10 Literature Search................................................................................................... 10 Study Selection ..................................................................................................... 10 Data Abstraction ................................................................................................... 12 Quality Assessment..............................................................................................
    [Show full text]
  • Emerging Drug List CANADIAN COORDINATING OFFICE for HEALTH ESCITALOPRAM TECHNOLOGY ASSESSMENT
    Emerging Drug List CANADIAN COORDINATING OFFICE FOR HEALTH ESCITALOPRAM TECHNOLOGY ASSESSMENT NO. 35 JANUARY 2003 Generic (Trade Name): Escitalopram (LexaproTM) Manufacturer: Forest Laboratories, Inc. Indication: For the treatment of major depressive disorders in adults.1 Current Regulatory Escitalopram was approved by the US FDA for the above indication in August 2002.2 It Status: was just recently launched in the US, according to the company's web site.3 It was launched in June 2002 in the UK under the trade name Cipralex by Lundbeck for both the treatment of depression and panic disorder.4 In Canada, escitalopram has been sub- mitted for review; no planned marketing date is available (Drug Information, Lundbeck Canada, Montreal: personal communication, 2002 Sep 30). Description: Escitalopram is the S(+) enantiomer of the chiral compound citalopram. It is a selective serotonin reuptake inhibitor that exerts activity in both depressive and anxiety disorders. After oral administration of a single dose, maximal concentrations are reached within three to four hours. It is extensively metabolized via the liver, with eight percent excreted unchanged by the kidneys. After a 20 mg dose, the elimination half-life (of the parent compound) ranges from 22 to 27 hours.5 Current Treatment: Options for the treatment of depressive disorders are vast and include selective serotonin norepinephrine reuptake inhibitors (SNRI), norepinephrine dopamine reuptake inhibitors (NDRI), serotonin-2 antagonists/reuptake inhibitors (SARI), noradrenergic/specific
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Cotard's Syndrome: Two Case Reports and a Brief Review of Literature
    Published online: 2019-09-26 Case Report Cotard’s syndrome: Two case reports and a brief review of literature Sandeep Grover, Jitender Aneja, Sonali Mahajan, Sannidhya Varma Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India ABSTRACT Cotard’s syndrome is a rare neuropsychiatric condition in which the patient denies existence of one’s own body to the extent of delusions of immortality. One of the consequences of Cotard’s syndrome is self‑starvation because of negation of existence of self. Although Cotard’s syndrome has been reported to be associated with various organic conditions and other forms of psychopathology, it is less often reported to be seen in patients with catatonia. In this report we present two cases of Cotard’s syndrome, both of whom had associated self‑starvation and nutritional deficiencies and one of whom had associated catatonia. Key words: Catatonia, Cotard’s syndrome, depression Introduction Case Report Cotard’s syndrome is a rare neuropsychiatric condition Case 1 characterized by anxious melancholia, delusions Mr. B, 65‑year‑old retired teacher who was pre‑morbidly of non‑existence concerning one’s own body to the well adjusted with no family history of mental illness, extent of delusions of immortality.[1] It has been most with personal history of smoking cigarettes in dependent commonly seen in patients with severe depression. pattern for last 30 years presented with an insidious However, now it is thought to be less common possibly onset mental illness of one and half years duration due to early institution of treatment in patients precipitated by psychosocial stressors.
    [Show full text]
  • Table of Contents
    TheJournalof VOLUME271 PHARMACOLOGY NUMBER 3 AND EXPERIMENTAL THERAPEUTICS Contents ANTI-INFLAMMATORIES Lecithinized Superoxide Dismutase Enhances Its R. Igarashi, J. Hoshino, A. Ochiai, 1672 Pharmacologic Potency by Increasing Its Cell Membrane Y. Morizawa and Y. Mizushima Affinity ANALGESICS Role of Endogenous Cholecystokinin in the Facilitation of Mu- Florence Noble, Claire Smadja and 1127 Mediated Antinociception by Delta.Opioid Agonists Bernard P. Roques Downloaded from GBR12909 Attenuates Cocaine-Induced Activation of Michael H. Baumann, George U. Char, 1216 Mesolimbic Dopamine Neurons in the Rat Brian R. Dc Costa, Kenner C. Rice and Richard B. Rothman Substance P N-Terminal Metabolites and Nitric Oxide Mediate Julie S. Kreeger, Kelley F. Kitto and 1281 Capsaicin-Induced Antinociception in the Adult Mouse Alice A. Larson Antinociceptive Actions of Dexmedetomidine and the Kappa- Juhana J. Idanpaan-Heikkila, Eija A. Kalso 1306 jpet.aspetjournals.org Opioid Agonist U.5O,488H against Noxious Thermal, and Timo Seppala Mechanical and Inflammatory Stimuli Involvement of NMDA Receptors in Naloxone-Induced Rustam Yu. Yukhananov and 1365 Contractions of the Isolated Guinea Pig ileum after Alice A. Larson Preincubation with Morphine Development of Cross-Tolerance between - Fang Fan, David R. Compton, Susan Ward, 1383 Tetrahydrocannabinol, CP 55,940 and WIN 55,212 Lawrence Melvin and Billy R. Martin at ASPET Journals on October 2, 2021 Antinociceptive and Response Rate-Altering Effects of Kappa Raymond C. Pitts and Linda A. Dykstra 1501 Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys The Influence of Pharmacogenetics on Opioid Analgesia: Jim Cleary, Gerd Mikus, Andrew Somogyi 1528 Studies with Codeine and Oxycodone in the Sprague-Dawley/ and Felix Bochner Dark Agouti Rat Model Selective Antagonism of Opioid Analgesia by a Sigma System Chih-Cheng Chien and 1583 Gavril W.
    [Show full text]
  • Measures and CDS for Safer Opioid Prescribing: a Literature Review
    Measures and CDS for Safer Opioid Prescribing: A Literature Review Measures and CDS for Safer Opioid Prescribing: A Literature Review Executive Summary The U.S. opioid epidemic continues to pose significant challenges for patients, families, clinicians, and public health policy. Opioids are responsible for an estimated 315,000 deaths (from 1999 to 2016) and have caused 115 deaths per day.1 In 2017, the U.S. Department of Health and Human Services declared the opioid epidemic a public health crisis.2 The total economic burden of opioid abuse in the United States has been estimated to be $78.5 billion per year.3 Although providing care for chronic opioid users is important, equally vital are efforts to prevent so-called opioid-naïve patients (patients with no history of opioid use) from developing regular opioid use, misuse, or abuse. However, much remains unclear regarding what role clinician prescribing habits play and what duration or dose of opioids may safely be prescribed without promoting long-term use.4,5 In 2013, ECRI Institute convened the Partnership for Health IT Patient Safety, and its component, single-topic-focused workgroups followed. For this subject, the Electronic Health Record Association (EHRA): Measures and Clinical Decision Support (CDS) for Safer Opioid Prescribing workgroup included members from the Healthcare Information and Management Systems Society (HIMSS) EHRA and the Partnership team. The project was oriented towards exploring methods to enable a synergistic cycle of performance measurement and identifying electronic health record (EHR)/health information technology (IT)–enabled approaches to support healthcare organizations’ ability to assess and measure opioid prescribing.
    [Show full text]
  • Arrhythmias Caused by Ondansetron: Case Report
    CorSalud 2019 Apr-Jun;11(2):171-174 Cuban Society of Cardiology ________________________ Case Report Arrhythmias caused by ondansetron: Case report Juan M. Chala Tandrón1, MD; Liset Jiménez Fernández2, MD, MSc; Zoila Armada Esmores2, MD, MSc; Yudileidy Brito Ferrer2, MD, MSc; Melba Zayas González2, MD, MSc; and Maiyen García Arcia2, MD 1 Department of Anesthesiology and Resuscitation, Hospital Oncológico Universitario “Dr. Celestino Hernández Robau”. Santa Clara, Villa Clara, Cuba. 2 Department of Pharmacology, Universidad de Ciencias Médicas de Villa Clara. Santa Clara, Villa Clara, Cuba, Cuba. Este artículo también está disponible en español ARTICLE INFORMATION ABSTRACT The ondansetron is used to prevent nausea and vomiting caused by chemothera- Received: April 4, 2019 py, radiotherapy and surgery, belonging to the serotonin 5-HT3 receptor antago- Accepted: May 21, 2019 nists, a natural substance that can cause nausea and vomiting, and it blocks its action. The ondansetron is packaged in the form of rapid disintegration tablets, as Competing interests a solution to be taken orally and in ampules, for parenteral use. The case of a 67- The authors declare no competing year-old female patient is presented, with a diagnosis of breast carcinoma, who interests underwent radical mastectomy with axillary dissection was performed, and who received chemotherapy with adriamycin, cyclophosphamide and paclitaxel; as well as ondansetron to treat nausea and vomiting. The patient presented a wide QRS complex tachycardia after taking the drug. Keywords: Ondansetron, Cardiac arrhythmias, Wide QRS complex tachycardia Arritmias provocadas por ondansetrón: Presentación de un caso RESUMEN El ondansetrón se usa para prevenir las náuseas y los vómitos causados por la quimioterapia, radioterapia y cirugías, pertenece a los antagonistas de receptores de serotonina 5-HT3, una sustancia natural que puede causar náuseas y vómitos, y bloquea su acción.
    [Show full text]
  • Department of Veterans Affairs § 4.130
    Department of Veterans Affairs § 4.130 agency shall evaluate it using a diag- termine whether a change in evalua- nostic code which represents the domi- tion is warranted. nant (more disabling) aspect of the (Authority: 38 U.S.C. 1155) condition (see § 4.14). [61 FR 52700, Oct. 8, 1996] (Authority: 38 U.S.C. 1155) § 4.130 Schedule of ratings—Mental [61 FR 52700, Oct. 8, 1996, as amended at 79 FR disorders. 45099, Aug. 4, 2014] The nomenclature employed in this § 4.127 Intellectual disability (intellec- portion of the rating schedule is based tual developmental disorder) and upon the American Psychiatric Asso- personality disorders. ciation’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edi- Intellectual disability (intellectual tion (DSM–5) (see § 4.125 for availability developmental disorder) and person- information). Rating agencies must be ality disorders are not diseases or inju- thoroughly familiar with this manual ries for compensation purposes, and, to properly implement the directives in except as provided in § 3.310(a) of this § 4.125 through § 4.129 and to apply the chapter, disability resulting from them general rating formula for mental dis- may not be service-connected. How- orders in § 4.130. The schedule for rating ever, disability resulting from a men- for mental disorders is set forth as fol- tal disorder that is superimposed upon lows: intellectual disability (intellectual de- 9201 Schizophrenia velopmental disorder) or a personality 9202 [Removed] disorder may be service-connected. 9203 [Removed] 9204 [Removed] (Authority: 38 U.S.C. 1155) 9205 [Removed] [79 FR 45100, Aug. 4, 2014] 9208 Delusional disorder 9210 Other specified and unspecified schizo- § 4.128 Convalescence ratings fol- phrenia spectrum and other psychotic lowing extended hospitalization.
    [Show full text]
  • The Effect of Depersonalization and Derealization Symptoms
    THE EFFECT OF DEPERSONALIZATION AND DEREALIZATION SYMPTOMS ON OLFACTION AND OLFACTORY HEDONICS Thesis Submitted to The College of Arts and Sciences of the UNIVERSITY OF DAYTON In Partial Fulfillment of the Requirements for The Degree of Master of Arts in Psychology By Rhiannon A. Gibbs UNIVERSITY OF DAYTON Dayton, Ohio May 2018 THE EFFECT OF DEPERSONALIZATION AND DEREALIZATION SYMPTOMS ON OLFACTION AND OLFACTORY HEDONICS Name: Gibbs, Rhiannon A. APPROVED BY: _______________________________________ Julie Walsh-Messinger, Ph.D. Faculty Advisor ______________________________________ Roger R. Reeb, Ph.D. Committee Member ______________________________________ Jackson A. Goodnight, Ph.D. Committee Member Concurrence: _______________________________________ Lee Dixon, Ph.D. Chair, Department of Psychology ii © Copyright by Rhiannon A. Gibbs All rights reserved 2018 ABSTRACT THE EFFECT OF DEPERSONALIZATION AND DEREALIZATION SYMPTOMS ON OLFACTION AND OLFACTORY HEDONICS Name: Gibbs, Rhiannon A. University of Dayton Advisor: Dr. Julie Walsh-Messinger. Depersonalization and derealization symptoms affect sensation, perception, and emotion, producing subjective experiences of unreality and affective numbing (Simeon, 2004). Abnormalities in the amygdala, which is associated with emotional reactions such as anxiety and fear (LeDoux, 1993), have been observed in depersonalization and derealization and other psychiatric disorders, such as anxiety and depression (Sierra & Berrios, 1998). Olfactory deficits have been posited as a potential marker for psychiatric
    [Show full text]